6,971 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 6,971 shares of the company’s stock, valued at approximately $317,000.

A number of other large investors have also modified their holdings of the company. Summit Securities Group LLC purchased a new position in shares of Janux Therapeutics in the 2nd quarter valued at about $29,000. Amalgamated Bank increased its position in shares of Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after buying an additional 368 shares in the last quarter. Plato Investment Management Ltd acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $42,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after buying an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Janux Therapeutics in the 2nd quarter valued at $151,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 3.2 %

Shares of NASDAQ:JANX opened at $59.61 on Wednesday. Janux Therapeutics, Inc. has a 52-week low of $7.79 and a 52-week high of $71.71. The stock has a market cap of $3.13 billion, a P/E ratio of -50.95 and a beta of 3.29. The business has a fifty day moving average of $53.37 and a two-hundred day moving average of $46.92.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics’s quarterly revenue was down 82.6% compared to the same quarter last year. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 50,000 shares of the stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the completion of the transaction, the insider now directly owns 67,592 shares in the company, valued at approximately $3,106,528.32. This represents a 42.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 49,231 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $46.45, for a total transaction of $2,286,779.95. Following the completion of the sale, the insider now owns 6,926 shares in the company, valued at approximately $321,712.70. This trade represents a 87.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 192,032 shares of company stock worth $9,512,515 in the last 90 days. Insiders own 29.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on JANX shares. BTIG Research upped their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. UBS Group started coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target for the company. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, December 3rd. Scotiabank increased their target price on Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a report on Wednesday, December 4th. Finally, Stifel Nicolaus lifted their price target on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Janux Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $89.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.